Article in Proceedings of the National Academy of Sciences of the United States of America, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
16 authors.
Sonali SharmaEye Research Centre, Oakland University William Beaumont School of Medicine, Rochester, MI 48309.ORCID 0009-0007-1009-3844
Gieth AlahdabEye Research Centre, Oakland University William Beaumont School of Medicine, Rochester, MI 48309.
Muhammad Nazmul HaqueEye Research Centre, Oakland University William Beaumont School of Medicine, Rochester, MI 48309.
Ikbal KarkoukliEye Research Centre, Oakland University William Beaumont School of Medicine, Rochester, MI 48309.ORCID 0009-0003-0933-3434
Alee AssafEye Research Centre, Oakland University William Beaumont School of Medicine, Rochester, MI 48309.
Yuichiro IshidaEye Research Centre, Oakland University William Beaumont School of Medicine, Rochester, MI 48309.ORCID 0000-0002-6690-8463
Ahmed Abu ElasrarDepartment of Ophthalmology, King Saud University, Riyadh 11461, Saudi Arabia.
Mohamed MoustafaEye Research Centre, Oakland University William Beaumont School of Medicine, Rochester, MI 48309.
Mohamed TarekEye Research Centre, Oakland University William Beaumont School of Medicine, Rochester, MI 48309.ORCID 0009-0003-3259-4536
Xiao ZhangEye Research Institute, Oakland University, Rochester, MI 48309.
Kenneth P MittonEye Research Centre, Oakland University William Beaumont School of Medicine, Rochester, MI 48309.
Natasha JosifovskaCenter for Eye Research and Innovative Diagnostics, Department of Ophthalmology, Oslo University Hospital, Oslo 0450, Norway.
Goran PetrovskiCenter for Eye Research and Innovative Diagnostics, Department of Ophthalmology, Oslo University Hospital, Oslo 0450, Norway.ORCID 0000-0003-2905-9252
Hiroki UeharuDepartment of Biologic and Materials Sciences and Prosthodontics, University of Michigan School of Dentistry, Ann Arbor, MI 48109.
Yuji MishinaDepartment of Biologic and Materials Sciences and Prosthodontics, University of Michigan School of Dentistry, Ann Arbor, MI 48109.ORCID 0000-0002-6268-4204
Mohamed Al-ShabraweyEye Research Centre, Oakland University William Beaumont School of Medicine, Rochester, MI 48309.ORCID 0000-0001-5362-7972
Funding
Regenerating cranial suture (Jaylynn Jones)R01DE027662 · NIDCR · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI HATCH, NAN E, MA, PETER X · 2018 to 2022
$2.6M
BMP2/ALKs Signaling System in Diabetic RetinopathyR01EY030054 · NEI · OAKLAND UNIVERSITY · PI Mohamed Al-Sayed Al-Shabrawey · 2020 to 2026
$2.0M
Toward Targeting GPR31 and GPR39 Signaling in Diabetic RetinopathyR21EY036537 · NEI · OAKLAND UNIVERSITY · PI AL-SHABRAWEY, MOHAMED AL-SAYED · 2024 to 2025
Retinal fibrosis is a blinding complication of proliferative diabetic retinopathy (PDR), proliferative vitreoretinopathy (PVR), age-related macular degeneration (AMD) and idiopathic epiretinal membrane (iERM), yet effective therapies remain lacking. The purpose of this study was to investigate the role of BMP2 and BMP4 (BMP2/4)-activin receptor-like kinase (ALK) signaling in retinal fibrosis. BMP2 was detected in the vitreous of PDR, PVR, and rhegmatogenous retinal detachment (RRD) samples at concentration of 70, 180, and 85 pg/mL respectively, whereas it was present only at trace levels or was undetectable in the vitreous of macular hole and idiopathic ERM samples (~0.1 pg/mL). PDR, PVR, and idiopathic ERMs exhibited strong immunoreactivity for BMP2, BMP4, ALK3 (Bmpr1a), pSMAD1/5/9, and pSMAD4. Formation of preretinal fibronectin-containing membranes resulted from intravitreal injection of wild-type mice with BMP2 and similar membranes formed in mice expressing constitutively active ALK3 (caBmpr1a). The presence of preretinal membrane in
Indexed as
Bone Morphogenetic Protein 2Bone Morphogenetic Protein 4RetinaSignal TransductionActivin Receptors, Type IIAnimalsBone Morphogenetic Protein Receptors, Type IDiabetic RetinopathyEpendymoglial CellsEpiretinal MembraneFibronectinsFibrosisHumansMicePyrimidinesRatsActivin Receptors, Type IIAcvrl1 protein, mouseBone Morphogenetic Protein 2Bone Morphogenetic Protein 4Bone Morphogenetic Protein Receptors, Type IFibronectinsPyrimidinesbone morphogenetic proteinproliferative diabetic retinopathyproliferative vitreoretinopathyretinal endothelial cellsretinal fibrosis
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Bone morphogenetic protein signaling as a key regulator of retinal fibrosis. · full record | OpenQuestion